journal article·2024-09Open access

Biomimetic Metal–Organic Framework Gated Nanoplatform for Sonodynamic Therapy against Extensively Drug Resistant Bacterial Lung Infection

Jianling Huang, Xiuwen Hong, Sixi Chen, Yucong He, Lixu Xie, Fenglin Gao, Chenghua Zhu, Xiao Jin, Haihao Yan, Yongxia Ye, Mingyue Shao, Xingran Du, Ganzhu Feng

Advanced Science· Volume 11· Issue 33

Abstract

Abstract Novel antimicrobial strategies are urgently needed to treat extensively drug‐resistant (XDR) bacterial infections due to the high mortality rate and lack of effective therapeutic agents. Herein, nanoengineered human umbilical cord mesenchymal stem cells (hUC‐MSCs), named PMZMU, are designed as a sonosensitizer for synergistic sonodynamic‐nano‐antimicrobial therapy against gram‐negative XDR bacteria. PMZMU is composed of a bacterial targeting peptide (UBI29‐41) modified hUC‐MSCs membrane (MSCm), a sonosensitizer meso‐tetra(4‐car‐boxyphenyl) porphine doped mesoporous organo‐silica nanoparticle and an acidity‐responsive metal–organic framework ZIF‐8. This innovative formulation enables efficient loading of polymyxin B, reduces off‐target drug release, increases circulation and targeting efficacy, and generates reactive oxygen species upon ultrasound irradiation. PMZMU exhibits remarkable in vitro inhibitory activity against four XDR bacteria: Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa (PA), and Escherichia coli. Taking advantage of the bacterial targeting ability of UBI29‐41 and the inflammatory chemotaxis of hUC‐MSC, PMZMU can be precisely delivered to lung infection sites thereby augmenting polymyxin B concentration. PMZMU‐mediated sonodynamic therapy significantly reduces bacterial burden, relieves inflammatory damage by promoting the polarization of macrophages toward M2 phenotype, and improves survival rates without introducing adverse events. Overall, this study offers promising strategies for treating deep‐tissue XDR bacterial infections, and guides the design and optimization of biomimetic nanomedicine.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Inhalation and Respiratory Drug Delivery · Ultrasound and Hyperthermia Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pulmonary and Critical Care Medicine The Second Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu 210011 China

Department of Pulmonary and Critical Care Medicine Qi Lu Hospital of Shandong University Wen hua xi Road 107# Jinan 250012 China

Department of Radiology Nanjing Medical University Affiliated Cancer Hospital Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Jiangsu 210009 China

Department of Respiratory and Critical Care Medicine The Affiliated Jiangning Hospital with Nanjing Medical University Nanjing 211100 China

Funding

National Natural Science Foundation of China · Beijing Medical and Health Foundation

References (42)

Show source-provided references
1. 10.1128/cmr.00031‐1910.1128/cmr.00031‐19 ↗
2. 10.3389/fbioe.2021.63627810.3389/fbioe.2021.636278 ↗
3. 10.1039/C7NP00023E10.1039/C7NP00023E ↗
4. 10.1007/s00253-020-10525-y10.1007/s00253-020-10525-y ↗
5. 10.1016/j.csbj.2020.08.00810.1016/j.csbj.2020.08.008 ↗
6. 10.1016/j.ijantimicag.2014.02.00910.1016/j.ijantimicag.2014.02.009 ↗
7. 10.1016/j.jconrel.2011.07.00210.1016/j.jconrel.2011.07.002 ↗
8. 10.1016/j.ijpharm.2017.12.03910.1016/j.ijpharm.2017.12.039 ↗
9. 10.1039/D1CS00659B10.1039/D1CS00659B ↗
10. 10.1021/acsami.7b0435110.1021/acsami.7b04351 ↗
11. 10.1002/adma.20180119810.1002/adma.201801198 ↗
12. 10.1039/C8TB02698J10.1039/C8TB02698J ↗
13. 10.1002/adma.20210756010.1002/adma.202107560 ↗
14. 10.1126/sciadv.abn170110.1126/sciadv.abn1701 ↗
15. 10.1016/j.cell.2010.02.04310.1016/j.cell.2010.02.043 ↗
16. 10.1021/ja211279u10.1021/ja211279u ↗
17. 10.1002/adma.20180361810.1002/adma.201803618 ↗
18. 10.1038/s41467-022-31500-310.1038/s41467-022-31500-3 ↗
19. 10.2217/nnm-2022-005110.2217/nnm-2022-0051 ↗
20. Song Y. · Front. Microbiol. · 2023 · 14
21. 10.1002/stem.18710.1002/stem.187 ↗
22. 10.4252/wjsc.v8.i3.7310.4252/wjsc.v8.i3.73 ↗
23. 10.1016/j.biopha.2023.11445110.1016/j.biopha.2023.114451 ↗
24. 10.1002/jcb.2304210.1002/jcb.23042 ↗
25. 10.1002/adhm.20240059310.1002/adhm.202400593 ↗
26. 10.1016/j.ultsonch.2023.10661710.1016/j.ultsonch.2023.106617 ↗
27. 10.1016/j.jcis.2024.04.12210.1016/j.jcis.2024.04.122 ↗
28. Pang X. · ACS Nano · 2019 · 13 · 2427
29. 10.1021/acsbiomaterials.1c0058710.1021/acsbiomaterials.1c00587 ↗
30. 10.1021/acsnano.9b0866710.1021/acsnano.9b08667 ↗
31. 10.1021/acsnano.1c0342410.1021/acsnano.1c03424 ↗
32. 10.1002/adfm.20211214510.1002/adfm.202112145 ↗
33. 10.1002/adma.20200604710.1002/adma.202006047 ↗
34. 10.1039/D2NR01847K10.1039/D2NR01847K ↗
35. 10.1002/adma.20200529510.1002/adma.202005295 ↗
36. 10.1021/acsnano.1c0342410.1021/acsnano.1c03424 ↗
37. 10.1002/adfm.20160392610.1002/adfm.201603926 ↗
38. 10.1038/s41579-020-0414-z10.1038/s41579-020-0414-z ↗
39. 10.1016/j.redox.2020.10150110.1016/j.redox.2020.101501 ↗
40. 10.1111/resp.1254210.1111/resp.12542 ↗
41. 10.1016/j.apsb.2021.10.02710.1016/j.apsb.2021.10.027 ↗
42. 10.1002/smll.20220185310.1002/smll.202201853 ↗